Intellia Therapeutics
NTLA
65 hedge funds and large institutions have $243M invested in Intellia Therapeutics in 2016 Q3 according to their latest regulatory filings, with 14 funds opening new positions, 21 increasing their positions, 14 reducing their positions, and 10 closing their positions.
50% more repeat investments, than reductions
Existing positions increased: 21 | Existing positions reduced: 14
40% more first-time investments, than exits
New positions opened: 14 | Existing positions closed: 10
5% more funds holding
Funds holding: 62 → 65 (+3)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
19% less capital invested
Capital invested by funds: $302M → $243M (-$58.7M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$2.6M |
| 2 |
SM
Sabby Management
Miami Beach,
Florida
|
+$2.03M |
| 3 |
BIT
BlackRock Institutional Trust
San Francisco,
California
|
+$1.29M |
| 4 |
Alyeska Investment Group
Chicago,
Illinois
|
+$677K |
| 5 |
PAM
Panagora Asset Management
Boston,
Massachusetts
|
+$605K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EC
EcoR1 Capital
San Francisco,
California
|
-$2.13M |
| 2 |
JP Morgan Chase
New York
|
-$1.3M |
| 3 |
EA
Emerald Acquisition
Seattle,
Washington
|
-$873K |
| 4 |
GL
GLG LLC
New York
|
-$730K |
| 5 |
LCM
Landscape Capital Management
Englewood,
New Jersey
|
-$582K |
NTLA Hedge Fund Activity: Q3 2016 in Review
65 of the 3,759 institutional investors tracked by Wall St. Rank reported a position in Intellia Therapeutics (NTLA) for Q3 2016, worth a combined $243M — down 19% from $302M a quarter earlier.
Buyers outnumbered sellers: 14 funds opened new NTLA positions and 10 closed out — a net gain of 4 holders — while 21 added to existing stakes and 14 trimmed.
The largest buyer was Millennium Management, opening a new position worth an estimated $2.6M. The largest seller was EcoR1 Capital, cutting an estimated $2.13M.
- 65 institutional investors held Intellia Therapeutics (NTLA) as of Q3 2016, up from 62 in Q2 2016.
- Funds reported $243M of Intellia Therapeutics stock for Q3 2016, down 19% quarter-over-quarter.
- 14 funds opened new Intellia Therapeutics positions in Q3 2016 and 10 closed out, a net change of +4 holders.
- The largest Intellia Therapeutics buyer in Q3 2016 was Millennium Management, an estimated $2.6M added.
- The largest Intellia Therapeutics seller in Q3 2016 was EcoR1 Capital, an estimated $2.13M sold.
Based on aggregated 13F filings for Q3 2016.